Ascelia Pharma Files New Patent Application for Orviglance

Nyheter Ascelia Pharma Nyheter alla bolag

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Ascelia Pharma Files New Patent Application for Orviglance

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the filing of a new patent application for its first-in-class orphan liver imaging drug Orviglance®.

In line with the strategy for Orviglance, the company has turned manufacturing knowledge and innovations into a patent application that, subject to approval and granting, further strengthens the market protection for Orviglance until 2046.

Magnus Corfitzen, CEO of Ascelia Pharma comments: “For both Ascelia Pharma and future commercialization partners, this patent has the potential to strengthen the commercial opportunity and lifetime value of Orviglance.”

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

About Orviglance
Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA). A clinical program of nine studies, including the pivotal global Phase 3 study SPARKLE, has successfully been completed with strong and consistent efficacy and safety results. The New Drug Application (NDA) has been submitted to the FDA.

Datum	2025-11-10, kl 09:15
Källa	MFN

Bifogade filer

Ascelia Pharma Files New Patent Application for Orviglance

LOGGA IN

Ascelia Pharma

Affiliate

Ascelia Pharma Files New Patent Application for Orviglance